Predicting the prognosis of hepatic arterial infusion chemotherapy in hepatocellular carcinoma

Figure 3 The prognostic in patients with hepatocellular carcinoma with different level of plasma ADAMTS13 and Von Willebrand factor receiving hepatic arterial infusion chemotherapy treatment[51]. A: ADAMTS13 levels were significantly higher in hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy treatment with stable disease (SD) + partial response (PR) than in those with progressive disease (PD) (P < 0.05); B: Von Willebrand factor (VWF) antigen levels were not different between patients with SD + PR and PD; C: VWF/ADAMTS13 ratio was significantly lower in patients with SD + PR than in those with PD (P < 0.05). SD: Stable disease; PR: Partial response; PD: Progressive disease; ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity; VWF: Von Willebrand factor; VWF:Ag: VWF antigen; VWF:Ag/ADAMTS13:AC ratio: Ratio of VWF:Ag to ADAMTS13:AC. Citation: Takaya H, Namisaki T, Moriya K, Shimozato N, Kaji K, Ogawa H, Ishida K, Tsuji Y, Kaya D, Takagi H, Fujinaga Y, Nishimura N, Sawada Y, Kawaratani H, Akahane T, Matsumoto M, Yoshiji H. Association between ADAMTS13 activity-VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma. World J Gastroenterol 2020; 26: 7232-7241. Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. The authors have obtained the permission for figure using (Supplementary material).